HCW Biologics Inc. Announces Exclusive Distribution Deal for HCW11-006

What Happened
HCW Biologics Inc. (HCWB) filed a Form 8-K reporting that on September 4, 2026 it entered into an Exclusive Distribution Agreement with Akron Biotech to commercialize and distribute HCW11-006 as a reagent for cell therapy manufacturing and other ex vivo uses (not for injectable therapies). The agreement grants Akron exclusive distribution rights worldwide except the People’s Republic of China, has a five‑year term from closing, and requires completion of due diligence and product testing with a closing no later than November 30, 2026. HCW also announced a Material Transfer Agreement to permit Akron’s further evaluation and said the parties will negotiate a Supply Agreement within 60 days of closing. A press release announcing the deal was furnished on September 8, 2026 (Exhibit 99.1).

Key Details

• Agreement signed: September 4, 2026; press release furnished: September 8, 2026.
• Territory: worldwide excluding the People’s Republic of China. Term: 5 years from closing.
• Closing conditions: satisfactory due diligence and product testing; closing must occur by November 30, 2026.
• Payment structure (under the contemplated Supply Agreement): $200,000 at closing, $100,000 within 30 days of the Supply Agreement, and $100,000 on each of the 1st and 2nd anniversaries; Akron will also pay quarterly for technical support as needed.
• If HCW terminates for convenience, HCW committed to continue supplying Product to support existing Akron customers to ensure a seamless transition.

Why It Matters
This agreement represents HCW’s first reported commercial distribution pathway for HCW11-006, potentially accelerating market access for the product as a reagent in cell therapy manufacturing. The deal includes near‑term cash consideration (advance payments totaling $500,000 across closing and early anniversaries under the Supply Agreement framework) plus ongoing technical‑support payments, which could provide modest near‑term revenue and commercial validation. Investors should note the closing is conditional on due diligence and testing (deadline November 30, 2026) and that HCW has continued supply obligations if it later terminates for convenience. Monitor subsequent filings for the final Distribution and Supply Agreements and any material financial terms or milestones.